Skip Navigation
Skip to contents

PHRP : Osong Public Health and Research Perspectives

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > Osong Public Health Res Perspect > Volume 11(1); 2020 > Article
Original Article
The Association Between Lung Function and Type 2 Diabetes in Koreans
Do-Youn Lee, Seung-min Nam
Osong Public Health and Research Perspectives 2020;11(1):27-33.
DOI: https://doi.org/10.24171/j.phrp.2020.11.1.05
Published online: February 28, 2020

Department of Physical Therapy, Daegu University, Gyeongsan, Korea

*Corresponding author: Seung-min Nam, Department of Physical Therapy, Daegu University, Gyeongsan, Korea, E-mail:20849606@hanmail.net
• Received: November 29, 2019   • Revised: January 22, 2020

Copyright ©2020, Korea Centers for Disease Control and Prevention

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

  • 6,327 Views
  • 140 Download
  • 6 Web of Science
  • 5 Crossref
  • 5 Scopus
prev next
  • Objectives
    This study was performed to test the association between lung function and type 2 diabetes mellitus (T2DM) in Korean patients.
  • Methods
    Data from the 6th Korea National Health and Nutrition Examination Survey (2013 to 2015) was used in this study. There were 3,466 individuals aged between 40 and 80 years, with T2DM, who had a smoking and alcohol status listed, and blood analysis (including blood pressure), were included in this study. Lung function, measured by spirometer ventilatory dysfunction was categorized into 3 patterns: normal, restrictive ventilatory dysfunction, and obstructive ventilatory dysfunction (OVD).
  • Results
    Based on multivariate logistic regression analysis, individuals with restrictive ventilatory dysfunction had an increased odds ratio (OR 1.615, 95% CI 1.137–2.294) for T2DM compared with individuals with normal ventilatory function, whereas OVD had no increase in the odds ratio (OR 1.169, 95 % CI 0.857–1.594). Model 1, which adjusted for age and gender, showed that the probability of having restrictive disorder was 1.559 times (95% CI 1.617–2.082) higher for prediabetes patients, and 2.320 times (95% CI 1.611–3.343) higher for T2DM patients, compared to normal individuals. For Model 4, which was fully adjusted for variables, the probability of having a restrictive disorder was 1.837 times higher for T2DM patients (95% CI 1.260–2.679).
  • Conclusion
    Restrictive ventilatory dysfunction, but not OVD, was associated independently with T2DM.
Reduced pulmonary function is defined by obstructive and restrictive patterns, and increases the risk of hypertension, and systematic low-grade inflammation in the lungs [1]. Additionally, a reduction in pulmonary function has been associated previously with an increased risk of death after adjusting for the patient’s age, gender, race, and smoking status [2]. Interestingly, several studies have reported a strong association between reduced lung function and type 2 diabetes mellitus (T2DM) [35].
A condition causing an obstructive pattern of reduced pulmonary function, hinders a person’s ability to exhale air from their lungs. This is observed as a significant reduction in the forced expiratory volume in 1 second (FEV1), in relation to the forced vital capacity (FVC) that can be displaced from the lung. Chronic obstructive pulmonary disease is the main type of obstructive lung disease [6].
On the other hand, a restrictive, but not an obstructive pattern of reduced pulmonary function, shows a significant reduction in both the FVC and FEV1, mainly due to a defect in thoracic compliance [7]. A restrictive pattern of reduced pulmonary function has been reported to be present in 10–15% of individuals older than 70 years, and can be caused by several pathological conditions, such as diabetes, obesity, heart failure, nonspecific lung fibrosis, and muscular weakness [8]. A restrictive pattern of reduced pulmonary function has also been reported to be associated with an increased risk of T2DM. Furthermore, in a previous study, diabetic patients showed a significantly reduced predicted FVC and FEV1 compared to non-diabetic patients at the baseline [9].
There is still a lack of large scale studies that have investigated diabetic and non-diabetic patients and lung dysfunction in Asians, and fewer studies that have investigated T2DM. As such, this study’s aim was to assess whether reduced pulmonary function or selective restrictive/obstructive pattern was associated with T2DM. Data from the Korea National Health and Nutrition Survey (KNHANES) was used in this study.
1. Data source and study population
This study used the data from the 6th KNHANES (2013–2015), which is a nationally representative population-based survey. The survey is cross-sectional and designed to examine the health and nutritional status of the non-institutionalized Korean population, and is conducted by the Division of Chronic Disease Surveillance, Korea Centers for Disease Control and Prevention. The KNHANES survey consists of 4 different components: 1) a health interview, 2) a health behavior survey, 3) a health examination, and 4) a nutrition survey. The survey information was collected by face-to-face interviews after the agreement of the individual, followed by a health examination.
Among the 22,948 individuals who participated in the KNHANES, a total of 14,116 (who had not had a spirometry test), and 940 others (not measured type 2 diabetes mellitus status) were excluded. In addition, individuals were selected for those ≥ 40 < 80 years old. Furthermore, individuals with an unknown smoking or alcohol status (n = 147) or lacking blood analysis (n = 4,279), including blood pressure, were all excluded from this study. After passing the study selection criteria, a total of 3,466 participants were included in this study for analysis.
2. Covariates
The general patient-characteristic information including age, gender, body mass index (BMI), waist circumference (WC), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, systolic blood pressure, diastolic blood pressure, and smoking status were included as covariates in the analysis model. The weight of the patient was measured on a calibrated balance-beam scale, and their height was measured in an upright position, using a stadiometer. The BMI was calculated by dividing weight (kg) by height (cm2). In the KNHANES, the respondents’ height and weight were measured by trained examiners. The WC was measured at the midpoint between the bottom of the rib cage and the top of the lateral border of the iliac crest during full expiration. Blood samples were collected from individuals in the morning after overnight fasting and were analyzed at a national central laboratory. The participants blood pressure was measured using a mercury sphygmomanometer, in a seated position, and after a 10-minute rest period. Two measurements were taken for every individual at a 5-minute interval. An average of 2 measurements was used for the data analyses. Cigarette smoking was categorized as never smoked, ex-smoker, or current smoker, and alcohol status was dichotomized as current user and non-user of cigarettes.
3. T2DM
The KNHANES classified an individual with diabetes using 3 different measures. Firstly, participants were asked whether or not they had a diabetic condition, and whether they had ever been diagnosed with diabetes by a physician. Individuals who self-reported that they had been diagnosed with diabetes by a physician were classified as diabetic. Secondly, individuals were classified as having diabetes during the health examination if their fasting glucose level was > 126 mg/dL. Lastly, individuals who self-reported that they were receiving treatment for diabetes were also classified as having a diabetic condition.
Based on these 3 indicators for diabetes, all individuals were recategorized into a diabetic and non-diabetic condition. In addition, the level of fasting glucose was divided into normal (< 100 mg/dL), prediabetic (100–125 mg/dL), and T2DM (≥ 126 mg/dL) to test for an association of ventilatory dysfunction, with an individual’s probability of developing T2DM. The KNHANES did not list the type of diabetes. Thus, it was assumed that if a respondent was diagnosed with diabetes before the age of 19 years, their diabetes was type 1, and it was assumed that none of them were affected by lung dysfunction.
4. Measurement of lung function
Lung function was measured by using a dry rolling seal spirometer (Model 2130; Sensor Medics, Yorba Linda, CA, USA) according to the criteria of the American Thoracic Society and the European Respiratory Society for standardization [10]. Spirometric data obtained on-site by clinical technicians were transferred to an internet review center for processing. The data were carefully examined and compared against criteria metrics for acceptability, reproducibility, and quality control. A principal investigator validated and stored the data in a Korea Centers for Disease Control and Prevention repository management system.
The participants were classified in groups according to their respiratory patterns: normal (FEV1/FVC ≥ 0.70, FVC ≥ 80% predicted), restrictive ventilatory dysfunction (RVD), (FVC < 80% predicted, FEV1/FVC ≥ 0.70), and obstructive ventilatory dysfunction (OVD), (FEV1/FVC < 0.70) [11].
5. Statistical analysis
Data were analyzed using SPSS 22.0 (IBM Corp., Armonk, NY, USA). Differences among groups were assessed using χ2 test for categorical variables, and the analysis of variance (ANOVA) for continuous variables. Bonferroni’s test was used for post hoc multiple comparisons in ANOVA. Multivariate logistic regression analyses were used to estimate the odds ratios (ORs) with 95% confidence intervals (CI) for T2DM, and prediabetes, using the fasting glucose levels of the normal group as a reference category, after adjusting for other clinical and biochemical variables. p < 0.05 were considered statistically significant.
The clinical characteristics of the individuals according to the ventilatory function are shown in Table 1. From the 3,466 participants, 2,663 (76.83%) were placed in the normal group, 315 (9.14%) in the RVD group, and 488 (14.07%) in the OVD group. When comparing the characteristics of the individuals’ ventilatory function, the prevalence rates of T2DM were reported at 13.7% for the normal group, 26.4% for the RVD group, and 23.0% for the OVD group. Individuals placed in the RVD group had higher fasting glucose levels, BMI, WC, and triglyceride values than the individuals in the normal and OVD groups.
Based on the fasting glucose status of the individuals (Table 2), there were 1,820 (53.52%) with normal values, 1,065 (30.73%) with prediabetes, and 581 (16.76%) with T2DM. Additionally, the prevalence of RVD in these groups was reported at 6.2%, 9.9%, and 14.3%, respectively, indicating that those with a higher fasting glucose level had a higher prevalence of RVD. Furthermore, a significant relationship was determined between a higher fasting glucose level and a lower FVC, FEV1, and FEV1/FVC.
Based on the multivariate logistic regression analysis, individuals with RVD were determined to have an increased OR (1.615, 95% CI 1.137–2.294) for T2DM when compared with individuals with normal ventilatory function (p < 0.01). However, with regards to OVD, the OR was similar (OR 1.169, 95% CI 0.857–1.594) and this was after fully adjusting for Model 4 (Table 3).
To determine whether ventilation dysfunction in individuals who were not classified as diabetic, but were likely to develop T2DM, a multivariate logistic regression analysis was performed using 3 fasting glucose groups: normal (< 100 mg/dL), prediabetic (100–125 mg/dL), and T2DM (≥ 126 mg/dL; Table 4). Model 1, which was adjusted for age and gender, showed the probability of having a restrictive lung disorder was 1.559 times higher (95% CI 1.617–2.082) in the prediabetes group (p < 0.01), and 2.320 times higher (95% CI 1.611–3.343) in the T2DM 1 (p < 0.001), compared to those in the normal group. In Model 4, which was fully adjusted for variables, the probability of having a restrictive lung disorder was 1.837 times (95% CI 1.260–2.679), which was significantly higher in the T2DM group compared with the normal group (p < 0.01). In contrast, there was no association between OVD and fasting glucose levels in any model.
The main finding of this study illustrated that ventilatory dysfunction was positively associated with abnormal glucose levels. Particularly a restrictive, but not obstructive respiratory pattern of reduced pulmonary function was determined to be linked to an increased OR for T2DM, which was independent of major confounding factors such as individual’s age, obesity, or smoking status.
A previous study using cross-sectional research that investigated the relationship between ventilatory dysfunction and glucose levels in patients, did not distinguish between restrictive and obstructive respiratory patterns of reduced pulmonary function, and demonstrated an independent association between low lung volume and insulin resistance [5]. In contrast, in this current study, an association between the restrictive ventilatory pattern of reduced pulmonary function and T2DM was determined.
A previous study has shown that there are insulin receptors in the lung pleura, and that hyperglycemia can contribute to reduced lung capacity [12]. The outcome of this current study was consistent with those results, in which the average FVC, FEV1, and FEV1/FVC values in the prediabetes and T2DM groups, showed a significant reduction in lung capacity in the fasting glucose levels compared to the group with normal glucose levels (non-diabetic). A follow-up study showed that only RVD was associated with the prevalence of diabetes in men and women in North America, which was not the case for OVD [8]. In addition, a study of Swedish patients reported a negative correlation between RVD and prevalence of diabetes [1,13].
Studies investigating the correlation between reduced lung function and diabetes among Asians remain scarce. It has been reported that Japanese men had a low FVC and FEV1, but not a low FEV1/FVC ratio, which increased the risk of diabetes after adjusting the model for fasting glucose levels [14]. In another study in Korean men, the lowest quartiles of FVC and FEV1 showed an increased OR for T2DM [15]. However, a major shortcoming of these 2 studies was that only men were investigated. In contrast, in this study the association between T2DM and RVD was determined for both men and women.
It has been overwhelmingly shown that smoking has a significant adverse effect on lung function [16]. Although smoking is the major cause of lung dysfunction, the risk for T2DM that is positively associated with RVD, is independent of patients’ smoking status in this current study (Model 4). Other studies have also shown that the relationship between RVD and the prevalence of diabetes is not significantly dependent on a patient’s smoking status [1,8]. This implies that smoking status does not have a clear effect on the positive association between T2DM and ventilatory dysfunction.
Previous studies have shown that there may be a relationship between reduced ventilatory function and T2DM. Obesity, a condition well-known for its association with hyperglycemia, is not only a risk factor for T2DM, but also a major cause of reduced lung capacity [17]. In a systemic review, the findings showed that obese individuals had a significantly lower FVC compared to healthy ones, and there was a significant negative association between the restive response pattern and obesity [18]. However, based on the results in this current study, the OR of RVD with the highest fasting glucose level (T2DM) was reported at 1.835 (95% CI 1.261–2.670) after adjusting for the BMI and WC. Furthermore, no significant difference was reported for prediabetes fasting glucose levels. Thus, obesity may explain the association between lung restriction and prediabetes, but it does not appear to be the stage of diabetes. Additionally, insulin resistance, illustrated by cells that fail to respond normally to the hormone insulin, and a major etiology of T2DM may alter the glucose absorption of thoracic muscles, thereby causing a reduced respiratory muscle function, and eventually the RVD [19,20].
Despite several meaningful findings in this study, there are some limitations that must be mentioned. Firstly, although the association between RVD and T2DM may be helpful in providing additional information about the nature of this relationship, determination of the rudimentary cause of RVD and OVD in patients was not possible. For this reason, future studies should include mechanisms to clarify the relationship between impaired lung function and T2DM. Secondly, the limitation of the KNHANES is that the individuals who participated in this survey have relatively mild-to-moderate levels of comorbidities, that is, a small number of severe cases of diabetes or lung dysfunction in patients influence the analysis of the results. This limitation might be overcome by further case-control or cohort studies. Thirdly, the KNHANES data were conducted on respiratory function tests in the over 40’s. Type 1 diabetes is commonly known to occur in children. For this reason, it was not possible to investigate the relationship between T1DM and RVD. Therefore, future research should investigate the correlation between ventilatory dysfunction and the type of diabetes. Despite these limitations, this current study has significant clinical and research implications because it is representative of the Korean population, and is a large sample size, which allowed multiple statistical adjustments increasing the sensitivity, validity and robustness of the study.
The findings of this study showed that RVD, but not OVD, in Koreans is highly associated with the prevalence of T2DM, regardless of various diabetes risk factors that may confuse or mediate these associations.

Conflicts of Interest

The authors have no conflicts of interest to declare.

  • 1. Engström G, Hedblad B, Nilsson P, et al. Lung function, insulin resistance and incidence of cardiovascular disease: A longitudinal cohort study. J Intern Med 2003;253(5). 574−81. PMID: 10.1046/j.1365-2796.2003.01138.x. PMID: 12702035.ArticlePubMed
  • 2. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and functional limitation: data from the Third National Health and Nutrition Examination. J Intern Med 2003;254(6). 540−7. PMID: 10.1111/j.1365-2796.2003.01211.x. PMID: 14641794.ArticlePubMed
  • 3. Lazarus R, Sparrow D, Weiss ST. Baseline ventilatory function predicts the development of higher levels of fasting insulin and fasting insulin resistance index: the Normative Aging Study. Eur Respir J 1998;12(3). 641−5. PMID: 10.1183/09031936.98.12030641. PMID: 9762793.ArticlePubMed
  • 4. Davis TM, Knuiman M, Kendall P, et al. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract 2000;50(2). 153−9. PMID: 10.1016/S0168-8227(00)00166-2. PMID: 10960726.ArticlePubMed
  • 5. Lawlor DA, Ebrahim S, Smith GD. Associations of measures of lung function with insulin resistance and type 2 diabetes: findings from the British Women’s Heart and Health Study. Diabetologia 2004;47(2). 195−203. PMID: 10.1007/s00125-003-1310-6. PMID: 14704837.ArticlePubMedPDF
  • 6. Toraldo DM, Nuccio FD, Scoditti E. Systemic inflammation in chronic obstructive pulmonary disease: May diet play a therapeutic role. J Allergy Ther 2013;S2:005.
  • 7. Reeves-Hoche MK, Meck R, Zwillich CW. Nasal CPAP: an objective evaluation of patient compliance. Am J Respir Crit Care Med 1994;149(1). 149−54. PMID: 10.1164/ajrccm.149.1.8111574. PMID: 8111574.ArticlePubMed
  • 8. Ford ES, Mannino DM. National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Prospective association between lung function and the incidence of diabetes: findings from the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Diabetes Care 2004;27(12). 2966−70. PMID: 10.2337/diacare.27.12.2966. PMID: 15562215.ArticlePubMed
  • 9. Lange P, Parner J, Schnohr P, et al. Copenhagen City Heart Study: longitudinal analysis of ventilatory capacity in diabetic and nondiabetic adults. Eur Respir J 2002;20(6). 1406−12. PMID: 10.1183/09031936.02.00050502. PMID: 12503696.ArticlePubMed
  • 10. Miller MR, Hankinson JATS, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26(2). 319−38. PMID: 10.1183/09031936.05.00034805. PMID: 16055882.ArticlePubMed
  • 11. Knudson RJ, Lebowitz MD, Holberg CJ, et al. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127(6). 725−34. PMID: 6859656.PubMed
  • 12. Kouritas VK, Hatzoglou C, Ioannou M, et al. Insulin alters the permeability of sheep pleura. Exp Clin Endocrinol Diabetes 2010;118(5). 304−9. PMID: 10.1055/s-0029-1233452.ArticlePubMed
  • 13. Engstrom G, Lind P, Hedblad B, et al. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation 2002;106(20). 2555−60. PMID: 10.1161/01.CIR.0000037220.00065.0D. PMID: 12427651.ArticlePubMed
  • 14. Heianza Y, Arase Y, Tsuji H, et al. Low lung function and risk of type 2 diabetes in Japanese men: the Toranomon Hospital Health Management Center Study 9 (TOPICS 9). Mayo Clin Proc 2012;87(9). 853−61. PMID: 10.1016/j.mayocp.2012.04.016. PMID: 22958989. PMID: 3538497.ArticlePubMedPMC
  • 15. Kwon CH, Rhee EJ, Song JU, et al. Reduced lung function is independently associated with increased risk of type 2 diabetes in Korean men. Cardiovasc Diabetol 2012;11:38PMID: 10.1186/1475-2840-11-38. PMID: 22524685. PMID: 3464774.ArticlePubMedPMC
  • 16. Jayes L, Haslam PL, Gratziou CG, et al. SmokeHaz: systematic reviews and meta-analyses of the effects of smoking on respiratory health. Chest 2016;150(1). 164−79. PMID: 10.1016/j.chest.2016.03.060. PMID: 27102185.ArticlePubMed
  • 17. Canoy D, Luben R, Welch A, et al. Abdominal obesity and respiratory function in men and women in the EPIC-Norfolk Study, United Kingdom. Am J Epidemiol 2004;159(12). 1140−9. PMID: 10.1093/aje/kwh155. PMID: 15191931.ArticlePubMedPDF
  • 18. Melo LC, Silva MAMD, Calles ACDN. Obesity and lung function: a systematic review. Einstein (Sao Paulo) 2014;12(1). 120−5. PMID: 10.1590/S1679-45082014RW2691.ArticlePubMedPMCPDF
  • 19. Lazarus R, Sparrow D, Weiss ST. Impaired ventilatory function and elevated insulin levels in nondiabetic males: the Normative Aging Study. Eur Respir J 1998;12(3). 635−40. PMID: 10.1183/09031936.98.12030635. PMID: 9762792.ArticlePubMed
  • 20. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106(4). 473−81. PMID: 10.1172/JCI10842. PMID: 10953022. PMID: 380258.ArticlePubMedPMC
Table 1
Clinical characteristics of individuals with normal, restrictive and obstructive ventilatory dysfunction.
Normal (n = 2,663) RVD (n = 315) OVD (n = 488)
Type 2 diabetes mellitus (%)* 13.7 26.4 23.0
Fasting glucose (mg/dL)* 104.10 ± 0.651 113.47 ± 2.267 107.74 ± 1.183§
Age (y)* 54.15 ± 0.261 57.92 ± 0.660 62.84 ± 0.568§
Male (%)* 48.3 52.3 78.5
BMI (kg/m2)* 24.44 ± 0.071 26.07 ± 0.217 24.24 ± 0.146†§
Waist circumference (cm)* 83.86 ± 0.213 88.60 ± 0.591 86.67 ± 0.429§
Systolic BP (mmHg)* 120.95 ± 0.384 125.54 ± 1.044 124.96 ± 0.740‡§
Diastolic BP (mmHg)* 77.86 ± 0.241 78.62 ± 0.760 76.73 ± 0.541
Total cholesterol* 199.18 ± 0.866 194.11 ± 2.238 192.24 ± 2.006§
LDL-cholesterol* 117.54 ± 0.792 114.87 ± 2.012†‡ 113.75 ± 1.980
HDL-cholesterol* 48.55 ± 0.328 45.60 ± 0.784 45.70 ± 0.578‡§
Triglyceride* 194.78 ± 5.101 198.25 ± 8.427 187.34 ± 6.925†‡
Smoking status (%)* (non-/ex-/current smoker) 55.1/23.6/21.3 55.1/24.7/20.3 30.2/36.6/33.2
Drinking (%) (non-/currently drinking) 26.2/75.5 32.4/67.6 24.5/75.5
FVC (% predicted)* 95.301 ± 0.209 74.788 ± 0.003 90.923 ± 0.814§
FEV 1* 2.932 ± 0.0156 2.295 ± 0.034 2.431 ± 0.036§
FEV1/FVC* 0.793 ± 0.001 0.795 ± 0.003 0.643 ± 0.003

Data are presented as means ± SD or n (%).

* p < 0.05 by ANOVA or chi-square test.

†, ‡, § The same letters indicate non-significant difference between groups based on Bonferoni multiple comparison test.

RVD = restrictive ventilatory dysfunction; OVD = obstructive ventilatory dysfunction; BMI = body mass index; WC = waist circumference; TG = triglyceride; LDL, low density lipoprotein; HDL = high density lipoprotein; SBP = systolic blood pressure; DBP = diastolic blood pressure; FBS = fasting blood sugar; FVC = forced vital capacity; FEV = forced expiratory volume.

Table 2
Respiratory function (spirometric parameters) in normal, impaired fasting glucose, and type 2 diabetic individuals.
Normal (n = 1,820) IFG (n = 1,065) T2DM (n = 581)
Rvd (%)* 6.2 9.9 14.3
Fasting glucose (mg/dL)* 91.20 ± 0.148 107.27 ± 0.219 148.12 ± 1.869§
Age (y)* 54.28 ± 0.310 55.85 ± 0.370 59.70 ± 0.502§
Male (%)* 43.7 62.2 63.1
BMI (kg/m2)* 23.91 ± 0.078 25.25 ± 0.17 25.62 ± 0.154§
Waist circumference (cm)* 82.21 ± 0.239 86.87 ± 0.285 88.227 ± 0.368§
Systolic BP (mmHg)* 119.25 ± 0.442 124.14 ± 0.550 126.07 ± 0.722§
Diastolic BP (mmHg)* 77.01 ± 0.277 79.49 ± 0.376 76.71 ± 0.490†§
Total cholesterol* 198.32 ± 0.944 201.15 ± 1.214 189.59 ± 2.107§
LDL-cholesterol* 118.67 ± 0.901 119.05 ± 1.157 106.28 ± 1.731§
HDL-cholesterol* 50.06 ± 0.391 46.60 ± 0.402 43.46 ± 0.531§
Triglyceride* 162.2978 ± 4.026 214.11 ± 6.750 258.47 ± 11.836§
Smoking status (%)* (non-/ex-/current smoker) 59.4/20.9/19.7 43.6/30.5/25.9 43.2/30.0/26.8
Drinking (%)* (non-/currently drinking) 27.6/72.4 22.2/77.8 31.3/68.7
FVC (% predicted)* 94.517 ± 0.296 91.847 ± 0.403 89.883 ± 0.561§
FEV1* 2.801 ± 0.019 2.872 ± 0.025 2.716 ± 0.037§
FEV1/FVC* 0.779 ± 0.001 0.770 ± 0.002 0.759 ± 0.004§

Data are presented as means ± SD or n (%).

* p < 0.05 by ANOVA or chi-square test.

†, ‡, § The same letters indicate non-significant difference between groups based on Bonferoni multiple comparison test.

BMI = body mass index; IFG = impaired fasting glucose; WC = waist circumference; TG = triglyceride; LDL, low density lipoprotein; HDL = high density lipoprotein; SBP = systolic blood pressure; DBP = diastolic blood pressure; FBS = fasting blood sugar; FVC = forced vital capacity; FEV = forced expiratory volume.

Table 3
The adjusted odds ratios for type 2 diabetes mellitus according to the ventilatory dysfunction by multivariate logistic regression analysis.
Ventilatory dysfunction Odds ratio 95% CI p
Model 1 Normal 1 (reference)
Restrictive 1.889** 1.341–2.611 < 0.001
Obstructive 1.171 0.865–1.586 0.306

Model 2 Normal 1
Restrictive 1.633* 1.151–2.318 0.006
Obstructive 1.093 0.805–1.484 0.569

Model 3 Normal 1
Restrictive 1.650* 1.151–2.366 0.007
Obstructive 1.162 0.850–1.588 0.347

Model 4 Normal 1
Restrictive 1.615* 1.137–2.294 0.008
Obstructive 1.169 0.857–1.594 0.323

Model 1: adjusted for age, gender.

Model 2: adjusted for age, gender, body mass index, waist circumference.

Model 3: adjusted for variables in Model 2 + total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride.

Model 4: adjusted for variables in Model 3 + systolic blood pressure, diastolic blood pressure, smoking status.

Reference category: individuals with non-type 2 DM.

* p < 0.01,

** p < 0.001.

Table 4
The adjusted odds ratios for ventilatory dysfunction according to the fasting glucose level by multivariate logistic regression analysis.
Fasting glucose Restrictive Obstructive
Model 1 Normal 1 (reference) 1
Prediabetes (100–125) 1.559 (1.617–2.082)* 0.805 (0.585–1.106)
T2DM (≥ 126) 2.320 (1.611–3.343)** 1.063 (0.770–1.468)

Model 2 Normal 1 1
Prediabetes (100–125) 1.259 (0.943–1.681) 0.779 (0.565–1.075)
T2DM (≥ 126) 1.835 (1.261–2.670)* 0.976 (0.706–1.350)

Model 3 Normal 1 1
Prediabetes (100–125) 1.295 (0.971–1.726) 0.803 (0.584–1.104)
T2DM (≥ 126) 1.882 (1.281–2.766)* 1.049 (0.7560–1.457)

Model 4 Normal 1 1
Prediabetes (100–125) 1.289 (0.966–1.720) 0.801 (0.581–1.104)
T2DM (≥ 126) 1.837 (1.260–2.679)* 1.054 (0.761–1.460)

Model 1: adjusted for age, gender.

Model 2: adjusted for age, gender, body mass index, waist circumference.

Model 3: adjusted for variables in Model 2 + total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride.

Model 4: adjusted for variables in Model 3 + systolic blood pressure, diastolic blood pressure, smoking status.

Reference category: individuals with normal spirometry.

* p < 0.01,

** p < 0.001.

T2DM = type 2 diabetes mellitus.

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Cardiorespiratory dynamics of type 2 diabetes mellitus: An extensive view of breathing and fitness challenges in a diabetes prevalent population
      Uzair Abbas, Shahbaz Ali Shah, Nisha Babar, Pashmina Agha, Mohiba Ali Khowaja, Maryam Nasrumminallah, Hibba Erum Arif, Niaz Hussain, Syed Mustafa Hasan, Israr Ahmed Baloch, Hidetaka Hamasaki
      PLOS ONE.2024; 19(7): e0303564.     CrossRef
    • Evaluating the impact of type 2 diabetes mellitus on pulmonary vascular function and the development of pulmonary fibrosis
      Nhlakanipho Mzimela, Nosipho Dimba, Aubrey Sosibo, Andile Khathi
      Frontiers in Endocrinology.2024;[Epub]     CrossRef
    • Causal relationship between type 2 diabetes and common respiratory system diseases: a two-sample Mendelian randomization analysis
      Jie Chen, Xiaofeng Zhang, Gengyun Sun
      Frontiers in Medicine.2024;[Epub]     CrossRef
    • Hidden chronic metabolic acidosis of diabetes type 2 (CMAD): Clues, causes and consequences
      Hayder A. Giha
      Reviews in Endocrine and Metabolic Disorders.2023; 24(4): 735.     CrossRef
    • Association of Pulmonary Function Decline over Time with Longitudinal Change of Glycated Hemoglobin in Participants without Diabetes Mellitus
      Wen-Hsien Lee, Da-Wei Wu, Ying-Chih Chen, Yi-Hsueh Liu, Wei-Sheng Liao, Szu-Chia Chen, Chih-Hsing Hung, Chao-Hung Kuo, Ho-Ming Su
      Journal of Personalized Medicine.2021; 11(10): 994.     CrossRef

    The Association Between Lung Function and Type 2 Diabetes in Koreans
    The Association Between Lung Function and Type 2 Diabetes in Koreans
    Normal (n = 2,663) RVD (n = 315) OVD (n = 488)
    Type 2 diabetes mellitus (%)* 13.7 26.4 23.0
    Fasting glucose (mg/dL)* 104.10 ± 0.651 113.47 ± 2.267 107.74 ± 1.183§
    Age (y)* 54.15 ± 0.261 57.92 ± 0.660 62.84 ± 0.568§
    Male (%)* 48.3 52.3 78.5
    BMI (kg/m2)* 24.44 ± 0.071 26.07 ± 0.217 24.24 ± 0.146†§
    Waist circumference (cm)* 83.86 ± 0.213 88.60 ± 0.591 86.67 ± 0.429§
    Systolic BP (mmHg)* 120.95 ± 0.384 125.54 ± 1.044 124.96 ± 0.740‡§
    Diastolic BP (mmHg)* 77.86 ± 0.241 78.62 ± 0.760 76.73 ± 0.541
    Total cholesterol* 199.18 ± 0.866 194.11 ± 2.238 192.24 ± 2.006§
    LDL-cholesterol* 117.54 ± 0.792 114.87 ± 2.012†‡ 113.75 ± 1.980
    HDL-cholesterol* 48.55 ± 0.328 45.60 ± 0.784 45.70 ± 0.578‡§
    Triglyceride* 194.78 ± 5.101 198.25 ± 8.427 187.34 ± 6.925†‡
    Smoking status (%)* (non-/ex-/current smoker) 55.1/23.6/21.3 55.1/24.7/20.3 30.2/36.6/33.2
    Drinking (%) (non-/currently drinking) 26.2/75.5 32.4/67.6 24.5/75.5
    FVC (% predicted)* 95.301 ± 0.209 74.788 ± 0.003 90.923 ± 0.814§
    FEV 1* 2.932 ± 0.0156 2.295 ± 0.034 2.431 ± 0.036§
    FEV1/FVC* 0.793 ± 0.001 0.795 ± 0.003 0.643 ± 0.003
    Normal (n = 1,820) IFG (n = 1,065) T2DM (n = 581)
    Rvd (%)* 6.2 9.9 14.3
    Fasting glucose (mg/dL)* 91.20 ± 0.148 107.27 ± 0.219 148.12 ± 1.869§
    Age (y)* 54.28 ± 0.310 55.85 ± 0.370 59.70 ± 0.502§
    Male (%)* 43.7 62.2 63.1
    BMI (kg/m2)* 23.91 ± 0.078 25.25 ± 0.17 25.62 ± 0.154§
    Waist circumference (cm)* 82.21 ± 0.239 86.87 ± 0.285 88.227 ± 0.368§
    Systolic BP (mmHg)* 119.25 ± 0.442 124.14 ± 0.550 126.07 ± 0.722§
    Diastolic BP (mmHg)* 77.01 ± 0.277 79.49 ± 0.376 76.71 ± 0.490†§
    Total cholesterol* 198.32 ± 0.944 201.15 ± 1.214 189.59 ± 2.107§
    LDL-cholesterol* 118.67 ± 0.901 119.05 ± 1.157 106.28 ± 1.731§
    HDL-cholesterol* 50.06 ± 0.391 46.60 ± 0.402 43.46 ± 0.531§
    Triglyceride* 162.2978 ± 4.026 214.11 ± 6.750 258.47 ± 11.836§
    Smoking status (%)* (non-/ex-/current smoker) 59.4/20.9/19.7 43.6/30.5/25.9 43.2/30.0/26.8
    Drinking (%)* (non-/currently drinking) 27.6/72.4 22.2/77.8 31.3/68.7
    FVC (% predicted)* 94.517 ± 0.296 91.847 ± 0.403 89.883 ± 0.561§
    FEV1* 2.801 ± 0.019 2.872 ± 0.025 2.716 ± 0.037§
    FEV1/FVC* 0.779 ± 0.001 0.770 ± 0.002 0.759 ± 0.004§
    Ventilatory dysfunction Odds ratio 95% CI p
    Model 1 Normal 1 (reference)
    Restrictive 1.889** 1.341–2.611 < 0.001
    Obstructive 1.171 0.865–1.586 0.306

    Model 2 Normal 1
    Restrictive 1.633* 1.151–2.318 0.006
    Obstructive 1.093 0.805–1.484 0.569

    Model 3 Normal 1
    Restrictive 1.650* 1.151–2.366 0.007
    Obstructive 1.162 0.850–1.588 0.347

    Model 4 Normal 1
    Restrictive 1.615* 1.137–2.294 0.008
    Obstructive 1.169 0.857–1.594 0.323
    Fasting glucose Restrictive Obstructive
    Model 1 Normal 1 (reference) 1
    Prediabetes (100–125) 1.559 (1.617–2.082)* 0.805 (0.585–1.106)
    T2DM (≥ 126) 2.320 (1.611–3.343)** 1.063 (0.770–1.468)

    Model 2 Normal 1 1
    Prediabetes (100–125) 1.259 (0.943–1.681) 0.779 (0.565–1.075)
    T2DM (≥ 126) 1.835 (1.261–2.670)* 0.976 (0.706–1.350)

    Model 3 Normal 1 1
    Prediabetes (100–125) 1.295 (0.971–1.726) 0.803 (0.584–1.104)
    T2DM (≥ 126) 1.882 (1.281–2.766)* 1.049 (0.7560–1.457)

    Model 4 Normal 1 1
    Prediabetes (100–125) 1.289 (0.966–1.720) 0.801 (0.581–1.104)
    T2DM (≥ 126) 1.837 (1.260–2.679)* 1.054 (0.761–1.460)
    Table 1 Clinical characteristics of individuals with normal, restrictive and obstructive ventilatory dysfunction.

    Data are presented as means ± SD or n (%).

    p < 0.05 by ANOVA or chi-square test.

    The same letters indicate non-significant difference between groups based on Bonferoni multiple comparison test.

    RVD = restrictive ventilatory dysfunction; OVD = obstructive ventilatory dysfunction; BMI = body mass index; WC = waist circumference; TG = triglyceride; LDL, low density lipoprotein; HDL = high density lipoprotein; SBP = systolic blood pressure; DBP = diastolic blood pressure; FBS = fasting blood sugar; FVC = forced vital capacity; FEV = forced expiratory volume.

    Table 2 Respiratory function (spirometric parameters) in normal, impaired fasting glucose, and type 2 diabetic individuals.

    Data are presented as means ± SD or n (%).

    p < 0.05 by ANOVA or chi-square test.

    The same letters indicate non-significant difference between groups based on Bonferoni multiple comparison test.

    BMI = body mass index; IFG = impaired fasting glucose; WC = waist circumference; TG = triglyceride; LDL, low density lipoprotein; HDL = high density lipoprotein; SBP = systolic blood pressure; DBP = diastolic blood pressure; FBS = fasting blood sugar; FVC = forced vital capacity; FEV = forced expiratory volume.

    Table 3 The adjusted odds ratios for type 2 diabetes mellitus according to the ventilatory dysfunction by multivariate logistic regression analysis.

    Model 1: adjusted for age, gender.

    Model 2: adjusted for age, gender, body mass index, waist circumference.

    Model 3: adjusted for variables in Model 2 + total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride.

    Model 4: adjusted for variables in Model 3 + systolic blood pressure, diastolic blood pressure, smoking status.

    Reference category: individuals with non-type 2 DM.

    p < 0.01,

    p < 0.001.

    Table 4 The adjusted odds ratios for ventilatory dysfunction according to the fasting glucose level by multivariate logistic regression analysis.

    Model 1: adjusted for age, gender.

    Model 2: adjusted for age, gender, body mass index, waist circumference.

    Model 3: adjusted for variables in Model 2 + total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride.

    Model 4: adjusted for variables in Model 3 + systolic blood pressure, diastolic blood pressure, smoking status.

    Reference category: individuals with normal spirometry.

    p < 0.01,

    p < 0.001.

    T2DM = type 2 diabetes mellitus.


    PHRP : Osong Public Health and Research Perspectives
    TOP